公司资料
BMYBristol-Myers Squibb Company 股价、新闻与催化剂
- 股票代码:
- BMY
- 交易所:
- NYSE
- 行业:
- Oncology, Immunotherapy
- 所在地:
- United States
股票表现
64.63 USD (+1.25%)
收盘价
最后更新: 2026年8月17日
111B USD
市值
股价为何变动
As of Aug 17, 2026, BMY closed up 1.25% at $64.63. No new same-company headline was identified in the current news window.
公司概览
Diversified Global Biopharma
Bristol Myers Squibb is a global biopharmaceutical company with commercial and development franchises spanning oncology, hematology, cardiovascular disease, immunology and neuroscience. Its growth portfolio combines established medicines, newer launches and late-stage candidates intended to offset the erosion of mature brands such as Revlimid and Pomalyst.
Oncology Franchise
The oncology business is anchored by the immune-checkpoint medicines Opdivo, Yervoy and Opdualag. Opdivo Qvantig adds a subcutaneous formulation intended to improve treatment convenience, while Krazati extends the portfolio into targeted therapy for KRAS G12C-mutated cancers. The pipeline includes antibody-drug conjugates and immunotherapies such as iza-bren, pumitamig, atigotatug and imzokitug across lung, breast and other solid tumors.
Hematology and Cell Therapy
Reblozyl treats anemia associated with myelodysplastic syndromes, while Breyanzi and Abecma provide CAR T-cell therapies for B-cell malignancies and multiple myeloma. Bristol Myers Squibb is also developing next-generation multiple-myeloma and lymphoma assets, including the CELMoDs iberdomide and mezigdomide, the CAR T candidates arlo-cel and zola-cel, and golcadomide.
Cardiovascular and Immunology
Eliquis is the company's major anticoagulant franchise, and Camzyos treats obstructive hypertrophic cardiomyopathy. The immunology portfolio includes Orencia and the TYK2 inhibitor Sotyktu. Late-stage expansion programs include milvexian for stroke prevention and atrial fibrillation, Sotyktu in systemic lupus erythematosus and Sjogren's disease, and admilparant in pulmonary fibrotic diseases.
Neuroscience
The neuroscience portfolio includes Zeposia and Cobenfy. Cobenfy is being expanded beyond schizophrenia through pivotal studies in Alzheimer's disease psychosis and agitation, bipolar disorder and cognition, while earlier programs target tau-mediated Alzheimer's disease, agitation and multiple-sclerosis spasticity.
Pipeline Renewal Model
Bristol Myers Squibb manages a broad pipeline across new molecular entities, lifecycle-management studies and early-stage platforms. The company uses internal research, partnerships and business development to replenish its portfolio while extending approved products into additional indications and treatment settings.
未来催化剂
- FDA action on iberdomide by the August 17, 2026 PDUFA date.
- Initiation of a fourth global pivotal study of iza-bren in first-line EGFR-mutated non-small cell lung cancer.
- Initiation of a Phase 2 study of pumitamig in combination with imzokitug.
- Registrational data for admilparant in idiopathic pulmonary fibrosis from ALOFT-IPF in 2026.
- Registrational data for arlo-cel in fourth-line or later multiple myeloma from QUINTESSENTIAL in 2026.
- Registrational data for milvexian in secondary stroke prevention from LIBREXIA-STROKE in 2026.
- Registrational data for RYZ101 in second-line or later gastroenteropancreatic neuroendocrine tumors from ACTION-1 in 2026.
- Pivotal data for Sotyktu in systemic lupus erythematosus from POETYK SLE-1 and POETYK SLE-2 in 2026.
- Early-stage data in 2026 from the BCMAxGPRC5D dual-targeting CAR T, golcadomide in first-line follicular lymphoma, imzokitug, delocamten, navlimetostat, pumitamig and zola-cel autoimmune programs.
- FDA action on mezigdomide by the May 13, 2027 PDUFA date.
- Registrational data in 2027 for golcadomide in high-risk first-line large B-cell lymphoma, milvexian in atrial fibrillation and zola-cel in systemic lupus erythematosus.
- Pivotal lifecycle-management data in 2027 for admilparant in progressive pulmonary fibrosis, Cobenfy in Alzheimer's disease psychosis and bipolar I disorder, mezigdomide in relapsed or refractory multiple myeloma and Sotyktu in Sjogren's disease.
- Registrational and pivotal data in 2028 across iza-bren, pumitamig, atigotatug, Krazati, Reblozyl, arlo-cel, zola-cel, Cobenfy and golcadomide expansion programs.
近期新闻
- 01
- 02
- 03
- 04
- 05
相似股票
商业成熟度、治疗领域或催化剂模式相近的同行公司。